Correlation Between Humacyte and Reviva Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Humacyte and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Humacyte and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Humacyte and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Humacyte and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Humacyte with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Humacyte and Reviva Pharmaceuticals.

Diversification Opportunities for Humacyte and Reviva Pharmaceuticals

0.7

Correlation Coefficient

Humacyte  Reviva Pharmaceuticals

Poor diversification

The 3 months correlation between Humacyte and Reviva is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Humacyte and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Humacyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Humacyte are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Humacyte i.e., Humacyte and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Humacyte and Reviva Pharmaceuticals

Assuming the 90 days horizon Humacyte is expected to under-perform the Reviva Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Humacyte is 2.0 times less risky than Reviva Pharmaceuticals. The stock trades about -0.23 of its potential returns per unit of risk. The Reviva Pharmaceuticals Holdings is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  17.00  in Reviva Pharmaceuticals Holdings on December 30, 2024 and sell it today you would lose (11.60) from holding Reviva Pharmaceuticals Holdings or give up 68.24% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Humacyte  vs.  Reviva Pharmaceuticals Holding

Humacyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Reviva Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Reviva Pharmaceuticals Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Humacyte and Reviva Pharmaceuticals

The main advantage of trading using opposite Humacyte and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Humacyte position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.

The idea behind Humacyte and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..